DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172122

Analysis of treatment outcome in multi-drug resistant tuberculosis patients treated under programmatic conditions

A. K. Janmeja, Deepak Aggarwal, Ruchika Dhillon

Abstract


Background: Programmatic management of MDR-TB has taken over the un-standardized and unsupervised treatment practice in India. However, despite being implemented in whole of country, the data on the program surveillance is scarce.  Hence the present study was sought to evaluate the treatment outcome in patients with MDR TB in Chandigarh being treated under programmatic conditions.

Methods: A retrospective study was carried out by enrolling all MDR-TB patients registered between January 2012 to December 2014. Medical records of 140 patients were scrutinized for necessary information on demographic, clinical parameters and previous TB treatment. Treatment outcomes to Cat IV anti-TB therapy, any interruptions in treatment, adverse drug reactions, culture conversion etc. were evaluated from the records.

Results: Of the 140 patients, 77 (55%) were declared cured, 11 (7.9%) completed treatment, 23 patients (16.4%) died, 13 (9.3%) defaulted on treatment, 5 (3.6%) had treatment failure and 11 (7.9%) were shifted to Cat V therapy. On comparison, BMI, haemoglobin, treatment outcome in previous ATT, treatment adherence and time to sputum culture conversion were significantly different in different treatment outcome groups.

Conclusions: The treatment success rate of MDR‑TB patients have shown improvement under programmatic conditions. Interventions to improve BMI and treatment adherence might further help to improve the success rate.


Keywords


Programmatic conditions, MDR-TB, Treatment outcome

Full Text:

PDF

References


World Health Organization. Global Tuberculosis Report; 2016.

Arora V, Sarin R, Singla R, Khalid UK, Mathuria K, Singla, N, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Indian J Chest Dis Allied Sci. 2007;49:75-9.

Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2014;5:145-9.

Patel S, Nimavat KB, Alpesh PB, Shukla LK, Shringarpure KS, Mehta KG, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDRTB) in Western India: A prospective study. J Infect Public Health. 2016;9:478-84.

Central TB division. Guidelines on programmatic management of drug resistant TB (PMDT) in India. India: Directorate General of Health Services MoHFW; 2012.

Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6:7.

Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PloS one. 2009;4:e6914.

Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61.

Jeon DS, Shin DO, Park SK, Seo JE, Seo HS, Cho YS, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci. 2011;26:33-41.

Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8:560-7.

Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13:976-81.

Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci. 2006;48:183-6.

Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16:1335-43.

Velayutham B, Nair D, Kannan T, Padmapriyadarsini C, Sachdeva KS, Bency J, et al. Factors associated with sputum culture conversion in multidrug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20:1671-6.

Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tubercul. 2012;92:397-403.

Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008;12:1182-9.

Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402-8.

Munoz-Torrico M, Caminero-Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. Arch de Bronconeumol. 2017;S0300-2896(16):30337-4.